Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

Fri, 11th Mar 2022 11:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

DeepVerge PLC, up 6.9% at 15.50 pence, 12-month range 12.50p-36.25p. Production orders for its Modern Water division in the first quarter grew to GBP5 million and stated that it is transitioning its business model. Deepverge says orders received this quarter reflect year-on-year growth of 39% compared to orders worth GBP3.6 million a year before. These new orders for the Modern Water division also represent the biggest first-quarter production order in the history of the division. The equipment is expected to be delivered this year. The company stated that it will still deliver units as it transitions to monitoring. This includes units for a Chinese State government department and multiple units on its Yangtze River project, which are capital equipment sales.

----------

Mkango Resources Ltd, up 12% at 26.49 pence, 12-month range 19.00p-37.50p. Secures financing from European Raw Materials Alliance for the development of a rare earth separation plant in Poland. This plant will be supplied with rare earth carbonate from Mkango's Songwe Hill deposit of rare earth elements in Malawi. Mkango says the project will aid the creation of a secure supply chain option for neodymium, praseodymium, dysprosium, and terbium for the EU.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 9.5% at USD26.30, 12-month range USD26.30-USD77.60. Sinks to 12-month low as its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

----------

Omega Diagnostics Group PLC, down 11% at 3.68 pence, 12-month range 3.68p-98.50p. Says its Visitect Covid-19 antigen test has not been approved by the UK Health Security Agency for professional use. As a result, the product will not be available for sale in the UK. The company continues to work with external study centres to ensure the deadline for submission of self-test CE Mark data is met on March 31. Omega says it believes the self-test market to be "more relevant in terms of opportunity".

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2019 16:02

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 18 AprilDomino's Pizza GroupSEGRORPC Group (re acquisition by Berry 19 events 22 events 23

Read more
3 Apr 2019 12:58

Gama Aviation Appoints Managing Director Of Major Shareholder As Chair

LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm

Read more
29 Mar 2019 09:16

Hutchison China MediTech Surufatinib Cancer Study Doses First Patient

LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by

Read more
11 Mar 2019 11:54

Hutchison loss widens as China legislation hampers revenue

(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.

Read more
11 Mar 2019 08:45

Hutchison China Meditech 2018 Loss Widens On New Government Policy

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to

Read more
29 Nov 2018 12:17

Hutchison Chi-Med enters four new drug test collaborations

(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.

Read more
26 Nov 2018 08:35

Hutchison China Meditech Starts Fruquintinib Capsules Sales In China

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with

Read more
19 Nov 2018 19:02

SVM UK Emerging Fund Beats Benchmark With Three Key Holdings

LONDON (Alliance News) - SVM UK Emerging Fund PLC on Monday said it had outpaced its benchmark in its most recent half year due to strong performances from three key holdings.As at 30, the

Read more
18 Oct 2018 10:09

Hutchison China Meditech Starts Phase I Study For Leukemia In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.The aim of the is

Read more
5 Sep 2018 08:28

Hutchison Gains Fruquintinib Capsules Approval As Cancer Drug In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.The of

Read more
27 Jul 2018 08:54

Hutchinson China Meditech Swings To Net Loss, Ups Annual Loss Estimate

LONDON (Alliance News) - Hutchison China Meditech Ltd on Friday raised its annual loss estimate by USD20 million after swinging to an interim net loss.For the six months to June 30, the a a

Read more
20 Jul 2018 15:50

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 23 July Ryanair HoldingsQ1 ResultsAscentialHalf Year Retail GroupHalf 24

Read more
4 Jun 2018 11:11

Hutchison China Cancer Trial Shows Clinically Meaningful Benefits

LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at

Read more
20 Apr 2018 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital

Read more
12 Mar 2018 08:53

Hutchison China Meditech 2017 Loss Widens Amid Rising Research Costs

LONDON (Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Monday annual losses widened due to increased and

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.